TY - JOUR AU - Stupp, R. AU - Mason, W. P. AU - Bent, M. J. AU - Weller, M. AU - Fisher, B. AU - Taphoorn, M. J. PY - 2005 DA - 2005// TI - Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma JO - N Engl J Med VL - 352 UR - https://doi.org/10.1056/NEJMoa043330 DO - 10.1056/NEJMoa043330 ID - Stupp2005 ER - TY - JOUR AU - Stupp, R. AU - Hegi, M. E. AU - Mason, W. P. AU - Bent, M. J. AU - Taphoorn, M. J. AU - Janzer, R. C. PY - 2009 DA - 2009// TI - Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial JO - Lancet Oncol VL - 10 UR - https://doi.org/10.1016/S1470-2045(09)70025-7 DO - 10.1016/S1470-2045(09)70025-7 ID - Stupp2009 ER - TY - JOUR AU - Vera, K. AU - Djafari, L. AU - Faivre, S. AU - Guillamo, J. S. AU - Djazouli, K. AU - Osorio, M. PY - 2004 DA - 2004// TI - Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors JO - Ann Oncol VL - 15 UR - https://doi.org/10.1093/annonc/mdh003 DO - 10.1093/annonc/mdh003 ID - Vera2004 ER - TY - JOUR AU - Nagasubramanian, R. AU - Dolan, M. E. PY - 2003 DA - 2003// TI - Temozolomide: realizing the promise and potential JO - Curr Opin Oncol VL - 15 UR - https://doi.org/10.1097/00001622-200311000-00002 DO - 10.1097/00001622-200311000-00002 ID - Nagasubramanian2003 ER - TY - JOUR AU - Ohgaki, H. AU - Kleihues, P. PY - 2005 DA - 2005// TI - Epidemiology and etiology of gliomas JO - Acta Neuropathol VL - 109 UR - https://doi.org/10.1007/s00401-005-0991-y DO - 10.1007/s00401-005-0991-y ID - Ohgaki2005 ER - TY - JOUR AU - Okamoto, Y. AU - Patre, P. L. AU - Burkhard, C. AU - Horstmann, S. AU - Jourde, B. AU - Fahey, M. PY - 2004 DA - 2004// TI - Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas JO - Acta Neuropathol VL - 108 UR - https://doi.org/10.1007/s00401-004-0861-z DO - 10.1007/s00401-004-0861-z ID - Okamoto2004 ER - TY - JOUR AU - Stewart, L. A. PY - 2002 DA - 2002// TI - Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials JO - Lancet VL - 359 UR - https://doi.org/10.1016/S0140-6736(02)08091-1 DO - 10.1016/S0140-6736(02)08091-1 ID - Stewart2002 ER - TY - JOUR AU - Lakka, S. S. AU - Rao, J. S. PY - 2008 DA - 2008// TI - Antiangiogenic therapy in brain tumors JO - Expert Rev Neurother VL - 8 UR - https://doi.org/10.1586/14737175.8.10.1457 DO - 10.1586/14737175.8.10.1457 ID - Lakka2008 ER - TY - JOUR AU - Klement, G. AU - Baruchel, S. AU - Rak, J. AU - Man, S. AU - Clark, K. AU - Hicklin, D. J. PY - 2000 DA - 2000// TI - Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity JO - J Clin Invest VL - 105 UR - https://doi.org/10.1172/JCI8829 DO - 10.1172/JCI8829 ID - Klement2000 ER - TY - JOUR AU - Browder, T. AU - Butterfield, C. E. AU - Kraling, B. M. AU - Shi, B. AU - Marshall, B. AU - O’Reilly, M. S. PY - 2000 DA - 2000// TI - Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer JO - Cancer Res VL - 60 ID - Browder2000 ER - TY - JOUR AU - Hanahan, D. AU - Bergers, G. AU - Bergsland, E. PY - 2000 DA - 2000// TI - Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice JO - J Clin Invest VL - 105 UR - https://doi.org/10.1172/JCI9872 DO - 10.1172/JCI9872 ID - Hanahan2000 ER - TY - JOUR AU - Emmenegger, U. AU - Man, S. AU - Shaked, Y. AU - Francia, G. AU - Wong, J. W. AU - Hicklin, D. J. PY - 2004 DA - 2004// TI - A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens JO - Cancer Res VL - 64 UR - https://doi.org/10.1158/0008-5472.CAN-04-0580 DO - 10.1158/0008-5472.CAN-04-0580 ID - Emmenegger2004 ER - TY - JOUR AU - Kim, J. T. AU - Kim, J. S. AU - Ko, K. W. AU - Kong, D. S. AU - Kang, C. M. AU - Kim, M. K. PY - 2006 DA - 2006// TI - Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas JO - Oncol Rep VL - 16 ID - Kim2006 ER - TY - JOUR AU - Brock, C. S. AU - Newlands, E. S. AU - Wedge, S. R. AU - Bower, M. AU - Evans, H. AU - Colquhoun, I. PY - 1998 DA - 1998// TI - Phase I trial of temozolomide using an extended continuous oral schedule JO - Cancer Res VL - 58 ID - Brock1998 ER - TY - JOUR AU - Kong, D. S. AU - Lee, J. I. AU - Kim, W. S. AU - Son, M. J. AU - do Lim, H. AU - Kim, S. T. PY - 2006 DA - 2006// TI - A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma JO - Oncol Rep VL - 16 ID - Kong2006 ER - TY - JOUR AU - Kong, D. S. AU - Lee, J. I. AU - Kim, J. H. AU - Kim, S. T. AU - Kim, W. S. AU - Suh, Y. L. PY - 2010 DA - 2010// TI - Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma JO - Neuro Oncol VL - 12 UR - https://doi.org/10.1093/neuonc/nop030 DO - 10.1093/neuonc/nop030 ID - Kong2010 ER - TY - JOUR AU - Chen, C. AU - Xu, T. AU - Lu, Y. AU - Chen, J. AU - Wu, S. PY - 2013 DA - 2013// TI - The efficacy of temozolomide for recurrent glioblastoma multiforme JO - Eur J Neurol VL - 20 UR - https://doi.org/10.1111/j.1468-1331.2012.03778.x DO - 10.1111/j.1468-1331.2012.03778.x ID - Chen2013 ER - TY - JOUR AU - Kerschbaumer, J. AU - Schmidt, F. A. AU - Grams, A. E. AU - Nowosielski, M. AU - Pinggera, D. AU - Brawanski, K. R. PY - 2015 DA - 2015// TI - Dual Anti-angiogenic Chemotherapy with Temozolomide and Celecoxib in Selected Patients with Malignant Glioma Not Eligible for Standard Treatment JO - Anticancer Res VL - 35 ID - Kerschbaumer2015 ER - TY - JOUR AU - Cui, Y. AU - Shu, X. O. AU - Gao, Y. T. AU - Cai, H. AU - Tao, M. H. AU - Zheng, W. PY - 2006 DA - 2006// TI - Association of ginseng use with survival and quality of life among breast cancer patients JO - Am J Epidemiol VL - 163 UR - https://doi.org/10.1093/aje/kwj087 DO - 10.1093/aje/kwj087 ID - Cui2006 ER - TY - JOUR AU - Kim, Y. J. AU - Zhang, D. AU - Yang, D. C. PY - 2015 DA - 2015// TI - Biosynthesis and biotechnological production of ginsenosides JO - Biotechnol Adv VL - 33 UR - https://doi.org/10.1016/j.biotechadv.2015.03.001 DO - 10.1016/j.biotechadv.2015.03.001 ID - Kim2015 ER - TY - JOUR AU - Zhang, F. AU - Li, M. AU - Wu, X. AU - Hu, Y. AU - Cao, Y. AU - Wang, X. PY - 2015 DA - 2015// TI - 20(S)-ginsenoside Rg3 promotes senescence and apoptosis in gallbladder cancer cells via the p53 pathway JO - Drug Des Devel Ther VL - 9 ID - Zhang2015 ER - TY - JOUR AU - Shan, X. AU - Tian, L. L. AU - Zhang, Y. M. AU - Wang, X. Q. AU - Yan, Q. AU - Liu, J. W. PY - 2015 DA - 2015// TI - Ginsenoside Rg3 suppresses FUT4 expression through inhibiting NF-kappaB/p65 signaling pathway to promote melanoma cell death JO - Int J Oncol VL - 47 ID - Shan2015 ER - TY - JOUR AU - Wang, L. AU - Li, X. AU - Song, Y. M. AU - Wang, B. AU - Zhang, F. R. AU - Yang, R. PY - 2015 DA - 2015// TI - Ginsenoside Rg3 sensitizes human non-small cell lung cancer cells to gamma-radiation by targeting the nuclear factor-kappaB pathway JO - Mol Med Rep VL - 12 ID - Wang2015 ER - TY - JOUR AU - Lee, Y. J. AU - Lee, S. AU - Ho, J. N. AU - Byun, S. S. AU - Hong, S. K. AU - Lee, S. E. PY - 2014 DA - 2014// TI - Synergistic antitumor effect of ginsenoside Rg3 and cisplatin in cisplatinresistant bladder tumor cell line JO - Oncol Rep VL - 32 ID - Lee2014 ER - TY - JOUR AU - Kim, D. G. AU - Jung, K. H. AU - Lee, D. G. AU - Yoon, J. H. AU - Choi, K. S. AU - Kwon, S. W. PY - 2014 DA - 2014// TI - 20(S)-Ginsenoside Rg3 is a novel inhibitor of autophagy and sensitizes hepatocellular carcinoma to doxorubicin JO - Oncotarget VL - 5 UR - https://doi.org/10.18632/oncotarget.2034 DO - 10.18632/oncotarget.2034 ID - Kim2014 ER - TY - JOUR AU - Kim, S. S. AU - Seong, S. AU - Kim, S. Y. PY - 2014 DA - 2014// TI - Synergistic effect of ginsenoside Rg3 with verapamil on the modulation of multidrug resistance in human acute myeloid leukemia cells JO - Oncol Lett VL - 7 ID - Kim2014 ER - TY - JOUR AU - Choi, Y. J. AU - Lee, H. J. AU - Kang, D. W. AU - Han, I. H. AU - Choi, B. K. AU - Cho, W. H. PY - 2013 DA - 2013// TI - Ginsenoside Rg3 induces apoptosis in the U87MG human glioblastoma cell line through the MEK signaling pathway and reactive oxygen species JO - Oncol Rep VL - 30 ID - Choi2013 ER - TY - JOUR AU - Sin, S. AU - Kim, S. Y. AU - Kim, S. S. PY - 2012 DA - 2012// TI - Chronic treatment with ginsenoside Rg3 induces Akt-dependent senescence in human glioma cells JO - Int J Oncol VL - 41 ID - Sin2012 ER - TY - JOUR AU - Kobayashi, N. AU - Allen, N. AU - Clendenon, N. R. AU - Ko, L. W. PY - 1980 DA - 1980// TI - An improved rat brain-tumor model JO - J Neurosurg VL - 53 UR - https://doi.org/10.3171/jns.1980.53.6.0808 DO - 10.3171/jns.1980.53.6.0808 ID - Kobayashi1980 ER - TY - JOUR AU - Gahramanov, S. AU - Muldoon, L. L. AU - Li, X. AU - Neuwelt, E. A. PY - 2011 DA - 2011// TI - Improved perfusion MR imaging assessment of intracerebral tumor blood volume and antiangiogenic therapy efficacy in a rat model with ferumoxytol JO - Radiology VL - 261 UR - https://doi.org/10.1148/radiol.11103503 DO - 10.1148/radiol.11103503 ID - Gahramanov2011 ER - TY - JOUR AU - Tolcher, A. W. AU - Gerson, S. L. AU - Denis, L. AU - Geyer, C. AU - Hammond, L. A. AU - Patnaik, A. PY - 2003 DA - 2003// TI - Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules JO - Br J Cancer VL - 88 UR - https://doi.org/10.1038/sj.bjc.6600827 DO - 10.1038/sj.bjc.6600827 ID - Tolcher2003 ER - TY - JOUR AU - Kurzen, H. AU - Schmitt, S. AU - Naher, H. AU - Mohler, T. PY - 2003 DA - 2003// TI - Inhibition of angiogenesis by non-toxic doses of temozolomide JO - Anticancer Drugs VL - 14 UR - https://doi.org/10.1097/00001813-200308000-00003 DO - 10.1097/00001813-200308000-00003 ID - Kurzen2003 ER - TY - JOUR AU - Tuettenberg, J. AU - Grobholz, R. AU - Korn, T. AU - Wenz, F. AU - Erber, R. AU - Vajkoczy, P. PY - 2005 DA - 2005// TI - Continuous low-dose chemotherapy plus inhibition of cyclooxygenase-2 as an antiangiogenic therapy of glioblastoma multiforme JO - J Cancer Res Clin Oncol VL - 131 UR - https://doi.org/10.1007/s00432-004-0620-5 DO - 10.1007/s00432-004-0620-5 ID - Tuettenberg2005 ER - TY - JOUR AU - Yue, P. Y. AU - Wong, D. Y. AU - Wu, P. K. AU - Leung, P. Y. AU - Mak, N. K. AU - Yeung, H. W. PY - 2006 DA - 2006// TI - The angiosuppressive effects of 20(R)- ginsenoside Rg3 JO - Biochem Pharmacol VL - 72 UR - https://doi.org/10.1016/j.bcp.2006.04.034 DO - 10.1016/j.bcp.2006.04.034 ID - Yue2006 ER - TY - JOUR AU - Jia, L. AU - Zhao, Y. AU - Liang, X. J. PY - 2009 DA - 2009// TI - Current evaluation of the millennium phytomedicine- ginseng (II): Collected chemical entities, modern pharmacology, and clinical applications emanated from traditional Chinese medicine JO - Curr Med Chem VL - 16 UR - https://doi.org/10.2174/092986709788803204 DO - 10.2174/092986709788803204 ID - Jia2009 ER - TY - JOUR AU - Zeng, D. AU - Wang, J. AU - Kong, P. AU - Chang, C. AU - Li, J. AU - Li, J. PY - 2014 DA - 2014// TI - Ginsenoside Rg3 inhibits HIF-1alpha and VEGF expression in patient with acute leukemia via inhibiting the activation of PI3K/Akt and ERK1/2 pathways JO - Int J Clin Exp Pathol VL - 7 ID - Zeng2014 ER - TY - JOUR AU - Kim, J. W. AU - Jung, S. Y. AU - Kwon, Y. H. AU - Lee, J. H. AU - Lee, Y. M. AU - Lee, B. Y. PY - 2012 DA - 2012// TI - Ginsenoside Rg3 attenuates tumor angiogenesis via inhibiting bioactivities of endothelial progenitor cells JO - Cancer Biol Ther VL - 13 UR - https://doi.org/10.4161/cbt.19599 DO - 10.4161/cbt.19599 ID - Kim2012 ER - TY - JOUR AU - Zhou, B. AU - Wang, J. AU - Yan, Z. PY - 2014 DA - 2014// TI - Ginsenoside Rg3 attenuates hepatoma VEGF overexpression after hepatic artery embolization in an orthotopic transplantation hepatocellular carcinoma rat model JO - Onco Targets Ther VL - 7 UR - https://doi.org/10.2147/OTT.S69830 DO - 10.2147/OTT.S69830 ID - Zhou2014 ER - TY - JOUR AU - Ng, W. Y. AU - Yang, M. S. PY - 2008 DA - 2008// TI - Effects of ginsenosides Re and Rg3 on intracellular redox state and cell proliferation in C6 glioma cells JO - Chin Med VL - 3 UR - https://doi.org/10.1186/1749-8546-3-8 DO - 10.1186/1749-8546-3-8 ID - Ng2008 ER - TY - JOUR AU - Yang, L. Q. AU - Wang, B. AU - Gan, H. AU - Fu, S. T. AU - Zhu, X. X. AU - Wu, Z. N. PY - 2012 DA - 2012// TI - Enhanced oral bioavailability and anti-tumor effect of paclitaxel by 20(s)-Ginsenoside Rg3 in vivo JO - Biopharm Drug Dispos VL - 33 UR - https://doi.org/10.1002/bdd.1806 DO - 10.1002/bdd.1806 ID - Yang2012 ER - TY - JOUR AU - Liu, T. G. AU - Huang, Y. AU - Cui, D. D. AU - Huang, X. B. AU - Mao, S. H. AU - Ji, L. L. PY - 2009 DA - 2009// TI - Inhibitory effect of ginsenoside Rg3 combined with gemcitabine on angiogenesis and growth of lung cancer in mice JO - BMC Cancer VL - 9 UR - https://doi.org/10.1186/1471-2407-9-250 DO - 10.1186/1471-2407-9-250 ID - Liu2009 ER - TY - JOUR AU - Jo, M. Y. AU - Kim, Y. G. AU - Kim, Y. AU - Lee, S. J. AU - Kim, M. H. AU - Joo, K. M. PY - 2012 DA - 2012// TI - Combined therapy of temozolomide and ZD6474 (vandetanib) effectively reduces glioblastoma tumor volume through anti-angiogenic and anti-proliferative mechanisms JO - Mol Med Report VL - 6 ID - Jo2012 ER - TY - JOUR AU - Lu, X. Y. AU - Cao, K. AU - Li, Q. Y. AU - Yuan, Z. C. AU - Lu, P. S. PY - 2012 DA - 2012// TI - The Synergistic Therapeutic Effect of Temozolomide and Hyperbaric Oxygen on Glioma U251 Cell Lines is Accompanied by Alterations in Vascular Endothelial Growth Factor and Multidrug Resistance-associated Protein-1 Levels JO - J Int Med Res VL - 40 UR - https://doi.org/10.1177/147323001204000318 DO - 10.1177/147323001204000318 ID - Lu2012 ER - TY - JOUR AU - Nallo, A. M. AU - Vidiri, A. AU - Marzi, S. AU - Mirri, A. AU - Fabi, A. AU - Carapella, C. M. PY - 2009 DA - 2009// TI - Quantitative analysis of CT-perfusion parameters in the evaluation of brain gliomas and metastases JO - J Exp Clin Cancer Res VL - 28 UR - https://doi.org/10.1186/1756-9966-28-38 DO - 10.1186/1756-9966-28-38 ID - Nallo2009 ER - TY - JOUR AU - Barajas, R. F. AU - Cha, S. PY - 2014 DA - 2014// TI - Benefits of dynamic susceptibility-weighted contrast-enhanced perfusion MRI for glioma diagnosis and therapy JO - CNS Oncol VL - 3 UR - https://doi.org/10.2217/cns.14.44 DO - 10.2217/cns.14.44 ID - Barajas2014 ER - TY - JOUR AU - Romano, A. AU - Rossi Espagnet, M. C. AU - Calabria, L. F. AU - Coppola, V. AU - Figa Talamanca, L. AU - Cipirani, V. PY - 2012 DA - 2012// TI - Clinical applications of dynamic susceptibility contrast perfusion-weighted MR imaging in brain tumours JO - Radiol Med VL - 117 UR - https://doi.org/10.1007/s11547-011-0715-4 DO - 10.1007/s11547-011-0715-4 ID - Romano2012 ER - TY - JOUR AU - Thomsen, H. AU - Steffensen, E. AU - Larsson, E. M. PY - 2012 DA - 2012// TI - Perfusion MRI (dynamic susceptibility contrast imaging) with different measurement approaches for the evaluation of blood flow and blood volume in human gliomas JO - Acta Radiol VL - 53 UR - https://doi.org/10.1258/ar.2011.110242 DO - 10.1258/ar.2011.110242 ID - Thomsen2012 ER - TY - JOUR AU - Hu, L. S. AU - Eschbacher, J. M. AU - Dueck, A. C. AU - Heiserman, J. E. AU - Liu, S. AU - Karis, J. P. PY - 2012 DA - 2012// TI - Correlations between perfusion MR imaging cerebral blood volume, microvessel quantification, and clinical outcome using stereotactic analysis in recurrent high-grade glioma JO - AJNR Am J Neuroradiol VL - 33 UR - https://doi.org/10.3174/ajnr.A2743 DO - 10.3174/ajnr.A2743 ID - Hu2012 ER - TY - JOUR AU - Vidiri, A. AU - Pace, A. AU - Fabi, A. AU - Maschio, M. AU - Latagliata, G. M. AU - Anelli, V. PY - 2012 DA - 2012// TI - Early perfusion changes in patients with recurrent high-grade brain tumor treated with Bevacizumab: preliminary results by a quantitative evaluation JO - J Exp Clin Cancer Res VL - 31 UR - https://doi.org/10.1186/1756-9966-31-33 DO - 10.1186/1756-9966-31-33 ID - Vidiri2012 ER -